Salvatore Privitera Sells 7,763 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 7,763 shares of AtriCure stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50. Following the completion of the sale, the insider owned 150,921 shares in the company, valued at approximately $7,923,352.50. This represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AtriCure Stock Down 0.2%

AtriCure stock opened at $52.46 on Friday. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $53.50. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of 249.82 and a beta of 1.26. The company’s 50-day moving average price is $39.67 and its two-hundred day moving average price is $32.70.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, analysts expect that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ATRC has been the subject of a number of analyst reports. BTIG Research lifted their target price on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Needham & Company LLC raised their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and a consensus target price of $52.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in AtriCure by 13.7% in the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after purchasing an additional 92,830 shares during the period. Assenagon Asset Management S.A. bought a new stake in AtriCure in the 2nd quarter valued at $1,744,000. Rice Hall James & Associates LLC acquired a new position in shares of AtriCure in the 2nd quarter valued at $3,755,000. F m Investments LLC acquired a new position in shares of AtriCure in the 4th quarter valued at $2,872,000. Finally, Man Group plc bought a new position in shares of AtriCure during the 2nd quarter worth about $684,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.